Day: May 31, 2020

Presented at ASCO 2020 Annual MeetingFirst complete response reported in 2nd line head and neck squamous cell carcinoma (HNSCC)Improving Overall Response Rate (iORR) in HNSCC, increasing to 38.9% (previously 33% iORR)Progression free survival (PFS) continues to improve in 1st line non-small cell lung cancer (NSCLC) patients, estimated at more than 9 monthsSYDNEY, Australia, June 01, 2020 (GLOBE NEWSWIRE) — Immutep Limited (ASX: IMM; NASDAQ: IMMP) announces new interim data from its ongoing Phase II TACTI-002 study. This data relates to the cut-off date of 4 May 2020 and shows improving efficacy results. The results were presented as a poster short talk by trial investigator, Dr Enriqueta Felip, of Vall d’Hebron University Hospital in Barcelona, Spain, at the 2020 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting....

First data from this collaboration study with Merck KGaA, Darmstadt, Germany, and Pfizer Inc and sponsor, IKF, presented at ASCOEncouraging early activity signals in a variety of cancer indicationsOverall, 33% of patients showed a Partial Response to the combination therapy of eftilagimod alpha and avelumab, with three patients not yet evaluableEftilagimod alpha continues to be well tolerated, including in combination with avelumabFurther data expected to be reported throughout 2020SYDNEY, Australia, June 01, 2020 (GLOBE NEWSWIRE) —  Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to report first interim data from its ongoing INSIGHT-004 Phase I clinical trial. The study is a phase I trial evaluating the combination of Immutep’s lead product candidate, eftilagimod alpha (“IMP321” or “efti”) with avelumab, a human anti-PD-L1 antibody,...

Kvalitena publicerar uppdaterad kvartalsrapport för det första kvartalet 2020. Uppdateringen avser korrekt bolagsnamn (Sterner Stenhus Fastigheter AB) avseende avyttrande andelar angivet under rubriken “Väsentliga händelser under det första kvartalet”.BilagaKvalitena AB (publ) – delårsrapport Q1 2020

Kvalitena publicerar kvartalsrapport för det första kvartalet 2020.BilagaKvalitena AB (publ) – delårsrapport Q1 2020

AUGA group, AB (hereinafter, the “Company”) published presentation of financial results for the 3 months of 2020 (see attachment), which will be presented in the Company’s investor conference webinar on the June 1 of 2020.To join the webinar, please register via following link: https://attendee.gotowebinar.com/register/3440357996802297355 . You will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to download the plug-in which will take only a few seconds. In case plug-in cannot be downloaded, a web browser which enables attending the webinar, will open automatically. The webinar will be recorded and available online for everyone at the company’s website on http://auga.lt/en/ and on Nasdaq Baltic youtube.com account.AttachmentPresentation...

AUGA group, AB (toliau – „Bendrovė“) paskelbė 2020 m. trijų mėnesių finansinių rezultatų prezentaciją (pridedama), kuri bus rodoma Bendrovės internetiniame seminare š.m. birželio 1 d. 9.00 val.Visus norinčius dalyvauti internetiniame seminare, prašome registruotis aktyvuojant šią nuorodą: https://attendee.gotowebinar.com/register/3440357996802297355 . Jums bus išsiųsta nuoroda prisijungti į internetinį seminarą ir instrukcija, kaip sėkmingai tai padaryti. Jungiantis į seminarą pirmą kartą, bus prašoma atsisiųsti nedidelį priedą interneto naršyklei. Internetinis seminaras bus įrašomas ir jo įrašas bus patalpintas įmonės internetiniame puslapyje www.auga.lt ir Nasdaq Baltic youtube.com paskyroje.PriedasPrezentacija Investuotojams 2020Q1

Dedalus France : changement de mode de participation à l’Assemblée Générale Mixte annuelle qui se tiendra à huis closLe Plessis Robinson, 31 mai 2020, Dedalus France, partenaire clé des établissements de santé dans les domaines de l’échange et du partage de données, du dossier patient, de la production de soins et des plateaux techniques (laboratoire, imagerie, pharmacie, oncologie), annonce que l’Assemblée Générale Mixte annuelle de la société Dedalus France se tiendra le 25 juin 2020 à 10 heures au siège social à huis clos hors la présence de ses actionnaires.Compte tenu de la situation exceptionnelle de pandémie de coronavirus, des restrictions liées aux rassemblements et aux déplacements imposées par la règlementation et en raison notamment de l’impossibilité de réunir au siège social l’ensemble des actionnaires dans des conditions...

U.S. Stock market has finally gained its pace after the re-opening of the economy and adaptation of the new normal way of living. Persistent Investors may have looked US President Donald Trump’s word war with China positively.The issue went fervid after Trump announced that they may withdraw their relationship with WHO or the World Health Organization saying that the organization is being controlled by the Chinese government. Trump said, “Chinese officials ignored their reporting obligations to the World Health Organization and pressured the World Health Organization to mislead the world when the virus was first discovered by Chinese authorities. Countless lives have been taken, and profound economic hardship has been inflicted all around the globe,” and added later, “Because they have failed to make the requested and...

The coronavirus pandemic has wounded many businesses around the globe, scratching every economy worldwide to almost a downfall. Oil prices went to bottom, stocks are struggling to keep up and many are now unemployed. Though government in all races are making every move they can to help their people, but things will never be easy not until this pandemic is solve. One business just made its consequential announcement this day. LATAM Airlines Group, the largest air carrier in Latin America, has just filed for bankruptcy in most part due to the Covid-19 pandemic and they’ve announced via statement in their website. In the statement it says, ‘The U.S. Chapter 11 financial reorganization process provides a clear and guided opportunity to work with our creditors and other stakeholders to reduce our debt, address commercial challenges that we,...

SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan, May 31, 2020 (GLOBE NEWSWIRE) — TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need in pain management, ophthalmology and oncology, today announced topline results from the TLC590 Phase II clinical trial, a randomized, double-blind, placebo- and comparator- controlled study of TLC590 in patients following bunionectomy. Results show that TLC590 demonstrated greater reductions in pain than both placebo and bupivacaine through 168 hours.TLC590 is a non-opioid, proprietary BioSeizer® sustained release formulation of ropivacaine. The trial compared TLC590 (228mg) with normal saline placebo and the current standard of care for postsurgical pain relief, bupivacaine (50mg), in 150 patients randomized...